The Latest Breaking News from CSL

HC Wainwright has removed Angion Biomedica Corp's (NASDAQ:ANGN) former lead candidate, ANG-3777, in acute kidney injury (AKI), from its valuation assessment. The analyst has reduced the price target from $50 to $32, with a Buy rating. In the Q4 earnings release, the Company decided to discontinue the development of ANG-3777 after disappointing data. The analyst…

IBD Stock Of The Day: Carlisle boasts accelerating growth and sees "pent-up demand." CSL stock is setting up just below a buy point.

Paul Bennetts was a successful businessman and NHS manager but now he is facing months behind bars

Shipyard inks pact with Dredging Corporation of India to build the 127-metre-long, 28-metre-wide vessel

An apparent easing in European geopolitical tensions supported US equity markets during the first half of the week. Here's a wrap of this week in markets.

Blood products giant CSL says that its ability to collect plasma has been improving as social mobility increases.

The Australian share market rises in afternoon trade, soaring oil and gas prices boost Santos' profit, while Fortescue Metals, CSL and Treasury Wine Estates reveal the impact of COVID-19 on their earnings.

The Australian Electoral Commission is about to release its annual political donations data. Journalists will have a field day if they know where to look.

Pact envisages mutual support in R&D among other areas